The EBV-specific antibody patterns of infectious mononucleosis (IM) patients were analyzed in relation to the onset of symptoms and clinical parameters during the acute phase of the disease. The antibody patterns varied considerably on admission. Three groups of patients were identified: one had not yet attained peak antibody titers, the second was at the peak and the third had passed the peak pattern. Patients with a "peak" current pattern had significantly higher lymphocyte counts, ASAT, ALAT, serum IgG and serum IgA concentrations than patients of the third group. Unexpectedly, there was no difference between the groups with regard to duration of sore throat and general malaise before admission. It thus seems that the lymphocyte proliferation during IM closely parallels the course of the EBV-specific antibody responses, whereas the onset of IM does not closely correlate to a specific stage of the antibody pattern.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365548609032302 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
EBV-specific T-cell immunity: relevance for multiple sclerosis.
Front Immunol
January 2025
Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
Genetic and environmental factors jointly determine the susceptibility to develop multiple sclerosis (MS). Improvements in the design of epidemiological studies have helped to identify consistent environmental risk associations such as the increased susceptibility for MS following Epstein-Barr virus (EBV) infection, while biological mechanisms that drive the association between EBV and MS remain incompletely understood. An increased and broadened repertoire of antibody and T-cell immune responses to EBV-encoded antigens, especially to the dominant CD4 T-cell EBV nuclear antigen 1 (EBNA1), is consistently observed in patients with MS, indicating that protective EBV-specific immune responses are deregulated in MS and potentially contribute to disease development.
View Article and Find Full Text PDFObjectives: Dysregulation of Epstein-Barr virus (EBV)-specific cellular immunity has been hypothesised as one of the contributing factors in the pathogenesis of systemic lupus erythematosus (SLE). Lupus nephritis is a major risk factor for overall morbidity in SLE. Immune-based strategies directed to EBV have been proposed as potential therapeutic strategy for SLE and lupus nephritis.
View Article and Find Full Text PDFAnalysis of the epidemiology and clinical characteristics of Epstein-Barr virus infection.
J Med Virol
October 2024
Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Article Synopsis
- The Epstein-Barr virus (EBV) is prevalent globally and can cause various diseases, with this study focusing on its epidemiological and clinical aspects in Chongqing, China, over a nine-year period.
- Among 13,584 inpatients, seropositivity rates for different EBV antibodies and DNA showed age-related trends, with high rates of acute infection in younger patients and an overall increased seropositivity with age.
- Common diseases associated with EBV included infectious mononucleosis and pneumonia, particularly in cases of primary infection, while reactivation of the virus was linked to conditions like pneumonia and nasopharyngeal carcinoma.
Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice.
Front Immunol
September 2024
Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, CA, United States.
Article Synopsis
- Epstein-Barr virus (EBV) is linked to various cancers and diseases, yet despite extensive research, an effective vaccine has not been licensed, largely due to past efforts focusing on a single protein.
- The study presents a new vaccine, MVA-EBV5-2, targeting five EBV entry glycoproteins, demonstrating genetic stability and the ability to produce strong immune responses in animal models.
- Results showed that this vaccine generated higher levels of neutralizing antibodies in mice and rhesus macaques compared to traditional methods, effectively reducing EBV infection in treated models.
Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.
Diagn Pathol
September 2024
Department of Hematology, Qilu Hospital of Shandong University, 107 West Wenhua Road, Jinan, Shandong, 250012, China.
Article Synopsis
- Post-transplant lymphoproliferative disorders (PTLD) are serious complications following organ transplants, particularly difficult to diagnose in the central nervous system (CNS) and associated with high mortality rates.
- The case study focuses on a patient with EBV-related CNS-PTLD and evaluates treatment effectiveness through a systematic review of 431 similar cases.
- Findings show that rituximab combined with EBV-specific therapies has a high response rate, suggesting it could be a promising treatment option for managing PTLD after transplants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!